Diagnostic criteria and laboratory tests for disseminated intravascular coagulation

Expert Review of Hematology

Volumn 5, Issue 6, 2012, Pages 643-652

  Wada, Hideo ^a   Matsumoto, Takeshi ^b   Hatada, Tuyoshi ^b  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Diagnostic criteria; Disseminated intravascular coagulation; Global coagulation tests; Hemostatic molecular marker; International Society on Thrombosis and Hemostasis; Japanese Association for Acute Medicine; Japanese Ministry of Health; Labor and Welfare; Non overt DIC; Overt DIC

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 7; CD14 ANTIGEN; D DIMER; DROTRECOGIN; FIBRIN; FIBRINOGEN DEGRADATION PRODUCT; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBOCYTE ANTIBODY; THROMBOPLASTIN; TOLL LIKE RECEPTOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AORTA ANEURYSM; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BONE MARROW SUPPRESSION; CELL DAMAGE; COLLAGEN DISEASE; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; IMMUNOASSAY; LABORATORY TEST; LEUKEMIA; LIVER DYSFUNCTION; MICROVASCULAR ENDOTHELIAL CELL; MORTALITY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH DIAGNOSTIC CRITERIA; REVIEW; SCORING SYSTEM; SEPSIS; STANDARDIZATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT;

BIOLOGICAL MARKERS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; PROGNOSIS;

EID: 84870863579     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.57     Document Type: Review

References (55)

1. Wada H. Disseminated intravascular coagulation. Clin. Chim. Acta 344(1-2), 13-21 (2004).
2. Colman RT, Robby SJ, Minna JD. Disseminated intravascular coagulation (DIC): an approach. Am. J. Med. 52, 679-689 (1974).
3. Al-Mondhiry H. Disseminated intravascular coagulation: experience in a major cancer center. Thromb. Diath. Haemorrh. 34(1), 181-193 (1975).
4. Siegal T, Seligsohn U, Aghai E, Modan M. Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb. Haemost. 39(1), 122-134 (1978).
5. Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb. Haemost. 43(1), 28-33 (1980).
6. Aoki N, Hasegawa H. About revised version of 'Auxiliary test findings and results for diagnostic' in diagnostic criteria for DIC: a study report by the research ommittee on blood coagulation on abnormalities in 1987. Special diseases designated by Japanese Ministry of Health and Welfare. 37-41 (1988).
7. Warren BL, Eid A, Singer P et al.; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286(15), 1869-1878 (2001).
8. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human protein C for severe sepsis. N. Engl. J. Med.. 8, 699-709 (2001).
9. Abraham E, Reinhart K, Opal S et al.; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2), 238-247 (2003).
10. Aoki N, Matsuda T, Saito H et al.; CTC-111-IM Clinical Research Group. A comparative double-blind randomized trial of activated protein C and unfractionated heparin in the treatment of disseminated intravascular coagulation. Int. J. Hematol. 75(5), 540-547 (2002).
11. Saito H, Maruyama I, Shimazaki S et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a Phase III, randomized, double-blind clinical trial. J. Thromb. Haemost. 5(1), 31-41 (2007).
12. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86(5), 1327-1330 (2001).
13. Bone RC. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 268(24), 3452-3455 (1992).
14. Gando S, Iba T, Eguchi Y et al.; Japanese Association for Acute Medicine Disseminated Intravascular Coagulation (JAAM DIC) Study Group. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit. Care Med. 34(3), 625-631 (2006).
15. Gando S, Wada H, Asakura H et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin. Appl. Thromb. Hemost. 11(1), 71-76 (2005).
16. Toh CH, Hoots WK; SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J. Thromb. Haemost. 5(3), 604-606 (2007).
17. Hayakawa M, Gando S, Hoshino H. A prospective comparison of new Japanese criteria for disseminated intravascular coagulation: new Japanese criteria versus ISTH criteria. Clin. Appl. Thromb. Hemost. 13(2), 172-181 (2007).
18. Egi M, Morimatsu H, Wiedermann CJ et al. Non-overt disseminated intravascular coagulation scoring for critically ill patients: the impact of antithrombin levels. Thromb. Haemost. 101(4), 696-705 (2009).
19. Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul. Fibrinolysis 16(1), 69-74 (2005).
20. Wada H, Hatada T, Okamoto K et al.; Japanese Society of Thrombosis Hemostasis/ DIC subcommittee. Modified non-overt DIC diagnostic criteria predict the early phase of overt-DIC. Am. J. Hematol. 85(9), 691-694 (2010).
21. Müller-Berghause G, Blombäck M, Ten Cate JW. Attempts to define disseminated intravascular coagulation.In: DIC: Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation. Müller-Berghause G, Blombäck M, Madlener K, Ten Cate JW (Eds). Elsevier Science Publishers BV, Amsterdam, The Netherlands, 3-8 (1993).
22. Müller-Berghaus G, Ten Cate H, Levi M. Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thromb. Haemost. 86, 1327-1330 (2001).
23. Wada H, Nagano T, Tomeoku M et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb. Res. 30(4), 315-322 (1983).
24. Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease. Blood Coagul. Fibrinolysis 6 (Suppl. 1), S26-S31 (1995).
25. Wada H, Kumeda Y, Ogasawara Z et al. Plasminogen-activators and their inhibitors in leukemic cell homogenates. Am. J. Hematol. 42(2), 166-170 (1993).
26. Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel W. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin. Thromb. Hemost. 29(3), 291-300 (2003).
27. Faulk WP, Labarrere CA, Carson SD. Tissue factor: identification and characterization of cell types in human placentae. Blood 76(1), 86-96 (1990).
28. Wada H, Kumeda Y, Ogasawara Z et al. Stimulation of tissue type plasminogenactivator by leukemic cell homogenates. Blood Coag Fibr. 4, 591-598 (1993).
29. Spencer DC, Pienaar NL, Atkinson PM. Disturbances of blood coagulation associated with Salmonella typhi infections. J. Infect. 16(2), 153-161 (1988).
30. Taylor FB Jr, Chang A, Ruf W et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ. Shock 33(3), 127-134 (1991).
31. Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 91(5), 1609-1615 (1998).
32. Creasey AA, Chang AC, Feigen L, Wün TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Invest. 91(6), 2850-2860 (1993).
33. Wada H, Tamaki S, Tanigawa M et al. Plasma levels of IL-1β in disseminated intravascular coagulation. Thromb Haemost. 65, 364-368 (1991).
34. Wada H, Ohiwa M, Kaneko T et al. Plasma level of tumor necrosis factor in disseminated intravascular coagulation. Am. J. Hematol. 37(3), 147-151 (1991).
35. Lien E, Means TK, Heine H et al. Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest. 105(4), 497-504 (2000).
36. Thomas JA. Toll genes and responsiveness to bacterial endotoxin. N. Engl. J. Med. 342, 664-665 (2000).
37. Sase T, Wada H, Kamikura Y et al. Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thromb. Haemost. 92(1), 132-139 (2004).
38. Ono T, Mimuro J, Madoiwa S et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107(2), 528-534 (2006).
39. Hyun J, Kim HK, Kim JE et al. Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. Thromb. Res. 124(1), 75-79 (2009).
40. Habe K, Wada H, Ito-Habe N et al. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb. Res. 129(5), 598-602 (2012).
41. Hatada T, Wada H, Nobori T et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb. Haemost. 94(5), 975-979 (2005).
42. Xu J, Zhang X, Pelayo R et al. Extracellular histones are major mediators of death in sepsis. Nat. Med. 15(11), 1318-1321 (2009).
43. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95(5), 1680-1686 (2000).
44. Taylor FB Jr, Kinasewitz GT, Lupu F. Pathophysiology, staging and therapy of severe sepsis in baboon models. J. Cell. Mol. Med. 16(4), 672-682 (2012).
45. Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl. Haematol. 49, 265-275 (1983).
46. Wada H, Gabazza EC, Asakura H et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Hemostasis and of the Japanese Ministry of Health and Welfare for overt DIC. Am. J. Hematol. 74(1), 17-22 (2003).
47. Takemitsu T, Wada H, Hatada T et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb. Haemost. 105(1), 40-44 (2011).
48. Wada H, Wakita Y, Nakase T et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb. Haemost. 74(3), 848-852 (1995).
49. Wada H, Minamikawa K, Wakita Y et al. Hemostatic study before onset of disseminated intravascular coagulation. Am. J. Hematol. 43(3), 190-194 (1993).
50. Wada H, Wakita Y, Nakase T et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am. J. Hematol. 51(4), 255-260 (1996).
51. Kawasugi K, Wada H, Hatada T et al.; Japanese Society of Thrombosis Hemostasis/ DIC Subcommittee. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb. Res. 128(2), 186-190 (2011).
52. Wada H, Mori Y, Shimura M et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am. J. Hematol. 58(3), 189-194 (1998).
53. Hatada T, Wada H, Kawasugi K et al.; Japanese Society of Thrombosis Hemostasis/ DIC subcommittee. Analysis of the cutoff values in fibrin-related markers for the diagnosis of overt DIC. Clin. Appl. Thromb. Hemost. 18(5), 495-500 (2012).
54. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22(7), 707-710 (1996).
55. Polderman KH, Girbes AR. Drug intervention trials in sepsis: divergent results. Lancet 363(9422), 1721-1723 (2004).